Cellectar Biosciences, Inc. (CLRB) to Release Earnings on Thursday
Cellectar Biosciences, Inc. (NASDAQ:CLRB) is set to release its earnings data after the market closes on Thursday, November 9th. Analysts expect Cellectar Biosciences to post earnings of ($0.25) per share for the quarter.
Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. On average, analysts expect Cellectar Biosciences to post $-0.92 EPS for the current fiscal year and $-0.92 EPS for the next fiscal year.
COPYRIGHT VIOLATION NOTICE: “Cellectar Biosciences, Inc. (CLRB) to Release Earnings on Thursday” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/02/cellectar-biosciences-inc-clrb-to-release-earnings-on-thursday.html.
A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Cellectar Biosciences from a “sell” rating to a “hold” rating in a research report on Monday, September 25th. ValuEngine upgraded shares of Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
A hedge fund recently raised its stake in Cellectar Biosciences stock. Vanguard Group Inc. boosted its holdings in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 31.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 147,208 shares of the biopharmaceutical company’s stock after buying an additional 35,482 shares during the quarter. Vanguard Group Inc. owned 1.09% of Cellectar Biosciences worth $240,000 as of its most recent SEC filing. 2.35% of the stock is owned by institutional investors.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.